about
A "dysautonomic" head-up tilt test pattern in elderly patients with neurocardiogenic syncope.Predictors of ventricular remodelling in patients with reperfused acute myocardial infarction and left ventricular dysfunction candidates for bone marrow cell therapy: insights from the BONAMI trial.Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial.Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trialCyclosporine before PCI in Patients with Acute Myocardial Infarction.Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial.Postconditioning in man.Postconditioning in acute myocardial infarction patients.Cardioprotection in the clinical setting.Infarct size reduction in patients with STEMI: why we can do it!Pharmacological approaches to reperfusion therapy.Delayed postconditioning: not too late?Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.Editor's Choice-Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease.close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design.Ca2+ currents in compensated hypertrophy and heart failure.Influence of cardiovascular risk factors on infarct size and interaction with mechanical ischaemic postconditioning in ST-elevation myocardial infarction.Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement.Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction.Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice.Postconditioning attenuates no-reflow in STEMI patients.Ischemic preconditioning decreases apoptosis in rat hearts in vivo.Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.Effect of cyclosporine on reperfusion injury in acute myocardial infarction.Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.Long-term benefit of postconditioning.Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients.Myocardial expression of a dominant-negative form of Daxx decreases infarct size and attenuates apoptosis in an in vivo mouse model of ischemia/reperfusion injury.Risk factors for silent myocardial ischemia in high-risk type 1 diabetic patients.Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction.Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients.Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients.Cardiac mGluR1 metabotropic receptors in cardioprotection.Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction.Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients.A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.Routine measurements of left and right ventricular output by gated blood pool emission tomography in comparison with thermodilution measurements: a preliminary study.Likely tuberculous myocarditis mimicking an acute coronary syndrome.Everolimus-eluting stent for the treatment of bare metal in-stent restenosis: clinical and angiographic outcomes at nine-month follow-up of XERES (Xience Evaluation in bare metal stent REStenosis) trial.
P50
Q33144927-5245C89E-3E88-4176-9EAA-9D4746781153Q33661061-DF4DEE38-4291-469B-BF8B-DDD02735A8C1Q33745962-0D5BED95-1F15-4CCC-B14C-74A9512B6EB0Q33762062-F0D4EBCB-5417-4966-8F97-51B94FC1A3DDQ34491582-17731538-178E-4501-AECB-0BE2032535F3Q36083241-7CD44534-8B54-400B-A9C5-45078F59BD6EQ36830855-7357FFC0-C2CB-481F-9DD9-B67CC3EF5D76Q37767722-38496D7D-928F-42DD-A65E-56D7D0272BF0Q37768703-5DD381E8-71BA-4693-8AEA-6C72BB1DD3C0Q37912851-779A6ECF-4B02-4889-A922-7F66FAF48370Q38003596-1435F457-77E2-44B8-A764-9BF46F377DD3Q38041846-4B57EE56-5C67-4660-B7DA-EB07A953BF92Q40043599-656A2873-9577-4F1B-8A4A-5AD252344A98Q40116416-FE24C5E5-8106-4FB4-BFE6-34DCA5839AC4Q40811767-AC435D74-C8A0-422F-B2AF-FD56F7DAEA4BQ40856650-3861C1D5-73CF-4D8E-A1D8-959579DFEC7DQ41995619-4DC0D6C6-7403-4900-8F14-F01649F9893FQ42905599-460C0D38-2AAE-416E-8E32-8FE4C0F58D0FQ43124905-E1AF4AD0-EFAD-43DE-8F6E-BF58A26E01FAQ45276644-0314DEB3-E4C3-4423-B8F3-13D964A26FDEQ46051532-C4859043-C4A9-47DF-9995-17F4ABEFBC85Q46069685-07C85776-D0AC-4CF8-8E99-6DAAF3A6222DQ46317170-1C4A9BCD-B3AF-484C-B073-EB3EC12373D4Q46453592-3229E47F-3757-4184-B900-E00BAE0EC8E5Q46670294-D2C183FC-805E-4049-84B0-96C5F4FC386AQ46758924-4DE33EE8-13C8-47B4-9B74-A76B8EB07442Q46847404-A0ADBE80-AB71-4DEE-97D5-8313987D8BDAQ46891649-FFF2C42B-6C89-4561-A761-E2AD2FD9FB0FQ47283376-86C30A69-E7A6-4217-A995-147045C38F69Q47305177-E5CF13A6-28AA-4257-B4B6-1E5457A82204Q47378251-39DE21A9-3D23-4715-A171-798F8D205D6CQ48635212-3948A205-815B-4BEC-9F4A-52C02D778C78Q50651011-A0F4D39A-5F47-42F4-9912-AC0AAB5DAC82Q51071029-4A4BFC2A-F6ED-405A-A81D-CA1753B1D78BQ51124858-73FFB43D-6701-47B1-9517-D352A3666549Q51741044-EA28723E-8718-4CE2-B3A7-5C02E865B393Q51793650-D59939D9-3F2B-4153-A602-468D07A5EB06Q52062561-E41EFA0F-8B48-42EE-8183-0B4A55DC0771Q53392462-4BE55A32-6864-4718-9891-49C39E39239DQ53655550-26E38A1E-66CB-4FDE-8C78-96675D627B68
P50
description
researcher ORCID ID = 0000-0001-7497-0294
@en
wetenschapper
@nl
name
Christophe Piot
@ast
Christophe Piot
@en
Christophe Piot
@es
Christophe Piot
@nl
type
label
Christophe Piot
@ast
Christophe Piot
@en
Christophe Piot
@es
Christophe Piot
@nl
prefLabel
Christophe Piot
@ast
Christophe Piot
@en
Christophe Piot
@es
Christophe Piot
@nl
P31
P496
0000-0001-7497-0294